Search Results

ImmunityBio and NantOmics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive T cells from individual patients.

NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

Feb. 19, 2020 13:00 UTC Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif.--( BUSINESS WIRE )-- NantOmics, LLC , the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed stu

Significant developments in cancer research were presented by NantHealth (NASDAQ: NH) and NantOmics at the ESMO conference in Munich, Germany this week.

NantOmics, LLC will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer.

NantOmics, LLC will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC).

NantOmics, LLC will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

NantHealth, Inc. and and NantOmics, will present data on next-generation sequencing of paired DNA and RNA analysis in patients with rare and ultra-rare cancers during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.